loading...| Preferred Name |
pimecrolimus |
|
| Synonyms |
SDZ ASM 981 |
|
| ID |
http://purl.bioontology.org/ontology/MESH/C117268 |
|
| altLabel |
SDZ ASM 981 Elidel 33-epi-chloro-33-desoxyascomycin ASM 981 SDZ-ASM-981 |
|
| cui |
C1263029 C1099414 C0971833 C0763387 |
|
| Has mapping qualifier | ||
| HM |
D016559/Q000031 |
|
| II |
D019696/Q000037 |
|
| Inverse of RB |
7KYV510875 0 |
|
| isa |
http://purl.bioontology.org/ontology/MESH/D065095 http://purl.bioontology.org/ontology/MESH/D003879 |
|
| LT |
TRD |
|
| Mapped to | ||
| MDA |
19990219 |
|
| MeSH Frequency |
662 |
|
| MMR |
20161222 |
|
| notation |
C117268 |
|
| PA |
D000894 D003879 D065095 D007166 |
|
| prefLabel |
pimecrolimus |
|
| SC |
1 |
|
| Scope Statement |
an ascomycin derivative; mechanism of action involves calcineurin inhibition, blockage of T cell activation, blocking signal transduction pathways in T cells, and inhibition of the synthesis of inflammatory cytokines, specifically Th1- and Th2-type cytokines |
|
| SRC |
J Pharmacol Exp Ther 1999 Feb;288(2):653-9 |
|
| TERMUI |
T331103 T331102 T331101 T472257 T460383 T472258 |
|
| TH |
US NLM (1999) NLM (2001) USAN (19XX) INN (19XX) DE FDA SRS (2015) |
|
| tui |
T109 T121 |